Asher Raz Miller | April 2026 | Confidential
Founder and CEO of a VC-backed bioproduction company. Brings rare dual fluency in biology and business.
Last 3 years deeply focused on the exosome sector, with extensive due diligence on cross-border operations, manufacturing partnerships, regulatory landscape, clinic/doctor relationships globally, and deep competitive knowledge.
10+ years designing scalable bioreactor systems up to 200L for therapeutic-grade biologics manufacturing.
End-to-end GMP process design across multiple product lines, from IND-enabling studies through commercial-scale manufacturing readiness.
Exosome based regenerative medicine projected market size, representing a high growth segment with accelerating clinical adoption.
Florida SB1768 are opening commercial avenues for US produced therapeutic exosomes — right now.
Signal's GMP certified, US produced, MSC derived exosomes offer a decisive quality and compliance advantage over key competitors:
The addressable buyer universe is substantial, spanning four high-value clinical segments with meaningful per-account revenue potential.
11,000–19,500 qualified accounts globally across all four segments, with strong concentration in the US, Mexico, and Asia-Pacific.
Conservative ramp of 40–80 activated accounts translates to $2.5M–$5.0M in first-year revenue — achievable with existing network and no cold outreach required.
$500M+ domestic market. 1,500–3,000 national buyers, with Florida as the highest-density state for aesthetic and longevity medicine. Favorable state-level legislation (SB1768) creates immediate commercial entry. CEO is Florida-based.
$200M regional market. Mexico is the anchor — a globally recognized medical tourism destination with 400–800 qualified buyers in-country alone. Existing relationships accelerate market entry and support cross-border patient referral flows.
$900M Far East market. Existing manufacturing partner relationships and an established APAC clinical network provide a significant structural advantage. Taiwan serves as the regional gateway for broader Asia-Pacific commercial expansion.
Three forces are converging simultaneously — and Signal sits at the exact intersection of all three.
GMP-certified, US produced, MSC derived exosomes. Regulatory ready, clinically credible, and meaningfully differentiated from every competitor in the current market.
2025–2026 US state legislation is creating a legal commercial runway that did not exist 18 months ago. First mover advantage is available — but only briefly.
A CEO with bioproduction depth, prior VC-backed company leadership, and an established exosome clinical network. Day one execution capacity — no ramp up period required.
Signal generates revenue immediately — through proven third party supply, while ExoTop production scales.
Aexo Bio (Taiwan) — TSC-derived exosomes, clinically characterized. Klothea (Austria) — Klotho exosomes, clinically validated. Available now.
Activate accounts, build distributor relationships, and establish a commercial footprint — before ExoTop is production-ready.
When ExoTop launches, Signal flips existing accounts to ExoTop supply. Customer base already built. Zero restart.
Signal purchases finished GMP-grade product from NurExone at cost and resells to clinics and physicians at margin. No production infrastructure required.
Signal: Exosome Distribution